AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-18876242_ITM" title="Facts and information about Dendreon announces Provenge significantly improves survival in men with advanced prostate cancer.">Dendreon announces Provenge significantly improves survival in men with advanced prostate cancer.</a>

Close Set up an RSS feed that alerts you when new articles from Asia Africa Intelligence Wire are available.

Frequently asked questions about RSS feeds

Dendreon announces Provenge significantly improves survival in men with advanced prostate cancer.

Asia Africa Intelligence Wire

| February 17, 2005 | COPYRIGHT 2003 Financial Times Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

(From Chemical Business NewsBase - Press Release)

Dendreon Corp announced that Provenge, the company's investigational immunotherapy for the treatment of prostate cancer, significantly improved survival in men with asymptomatic, meta-static androgen-independent prostate cancer when compared to patients receiving placebo. The final data from the D9901 study will be presented at the University of California, San Francisco, on 19 Feb 2005 at the 2005 Multidisciplinary Prostate Cancer Symposium. According to the final three-year intent-to-treat analysis of the company's first randomised Phase III clinical study (D9901), patients receiving Provenge had a 4.5 month…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Cell Genesys Reports Data on an Association Between Immune Response and...: Press release article from: Business Wire April 15, 2008 700+ words
...immunotherapy for prostate cancer is an investigational...in PSA levels. Patients receiving the three highest...cell monitoring. Patients receiving the two highest...immunotherapy for prostate cancer used in combination...


Viagra Effective Over Long Term for Prostate Cancer Patients Receiving...: Press release article from: PR Newswire October 20, 2003 700+ words
...CRT) and brachytherapy for prostate cancer, the medication successfully...effectiveness of Viagra for prostate cancer patients receiving radiation therapy, but there...the trial followed 363 prostate cancer patients at Memorial Sloan...


New Data Demonstrates Survival Advantage in Advanced Prostate Cancer Patients...: Press release article from: PR Newswire June 22, 2004 700+ words
...treatment of bone metastases secondary to prostate cancer. QUADRAMET is currently available...patients with hormone-refractory prostate cancer and pain due to bone metastases were...approach in patients with advanced prostate cancer. Improved clinical outcomes may expand...


Leading Cancer Centers Commence Clinical Study for Prostate Cancer Patients...: Press release article from: PR Newswire July 20, 2005 700+ words
...clinical studies for patients with prostate cancer receiving external beam radiation...experience in radiation therapy for prostate cancer and desire to bring new technology...232,000 men will be diagnosed with prostate cancer, more than half of whom will receive...


New data demonstrates survival advantage in advanced prostate cancer patients...: News wire article from: Asia Africa Intelligence Wire June 22, 2004 700+ words
...chemotherapy for the treatment of bone metastases secondary to prostate cancer. Between Jan 2000 and Apr 2003, a total of 30 patients with hormone-refractory prostate cancer and pain due to bone metastases were enrolled in a study evaluating...


Zoledronic acid protects bone in prostate cancer: the drug reduced the risk of...: Magazine article from: Internal Medicine News MacNeil, Jane Salodof June 1, 2006 700+ words
...skeletal complications in advanced prostate cancer patients and prevented bone loss in...sponsored symposium on skeletal events in prostate cancer said that bone complications are underrecognized...men receiving hormone therapy for prostate cancer. Putting these numbers in ...


Cell Genesys Reports Additional Encouraging Results From Phase I/II Trial Of...: Press release article from: PR Newswire April 13, 1999 700+ words
...the blood of patients receiving GVAX(TM) has...gene-modified prostate cancer cells comprising...treatment for their prostate cancer. Patients received...blood from the patients receiving GVAX(TM) prostate cancer vaccine revealed...


Investigators at Veterans Administration, Hematology-Oncology Division publish...: Newspaper article from: Blood Weekly March 26, 2009 700+ words
...body image among men with prostate cancer who were either prescribed...years of age or older with prostate cancer recruited from the oncology...ADT naive. FOR NURSING: Patients receiving ADT for prostate cancer may be at greater risk...


Primary hormone induced meningiomas may result from prostate cancer therapy.: Newspaper article from: Health & Medicine Week October 13, 2003 700+ words
...are a risk in patients receiving hormone therapy as treatment for prostate cancer; meningioma...patients with prostate cancer and a history...intracranial growths in patients receiving hormonal therapy for prostate cancer are metastatic...


Bicalutamide: do not use in localized prostate cancer.(Regulatory and Safety...: Magazine article from: WHO Drug Information September 22, 2003 700+ words
...noted that metastatic prostate cancer patients taking bicalutamide...patients with localized prostate cancer, the balanced risk...uses are not affected. Patients receiving biculatimide for localized prostate cancer should be reviewed at...

For more facts and information, see all results

The AccessMyLibrary advertising network includes: